Promising results have been obtained using CCL2 siRNA, CCR2 siRNA, CCL2-neutralizing antibodies, CCL2 inhibitors, or CCR2 antagonists to treat tumours like breast cancer [112], glioma [113], and hepatocellular cancer [114] in laboratory animals that received cancer cell implantation. The gene discussed is CCR2; the disease is central nervous system cancer.